Quantitative analysis of the association between sulfotransferase isoform 1A1 polymorphism and risk of urothelial carcinoma

Liu,Kang; Ye,Jiaxin; Huang,Yuan; Qin,Chao; Li,Pu; Liu,Bianjiang; Li,Jie; Yin,Changjun

doi:10.3892/mco.2014.406

Quantitative analysis of the association between sulfotransferase isoform 1A1 polymorphism and risk of urothelial carcinoma

Authors:
- Kang Liu
- Jiaxin Ye
- Yuan Huang
- Chao Qin
- Pu Li
- Bianjiang Liu
- Jie Li
- Changjun Yin
View Affiliations

Affiliations: Department of Urology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu 210029, P.R. China
Published online on: September 1, 2014 https://doi.org/10.3892/mco.2014.406
Pages: 93-100

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Sulfotransferase isoform 1A1 (SULT1A1) is a member of the sulfotransferase family that plays an important role in the biotransformation of numerous carcinogenic and mutagenic compounds through sulfation. A number of case‑control studies were conducted to investigate the association between the Arg213His polymorphism in SULT1A1 and the risk of urothelial carcinoma (UC) in humans. However, the results were inconsistent. A meta‑analysis based on 10 case‑control studies was performed to address this issue. Crude odds ratios (ORs) with 95% confidence intervals (CIs) were calculated to estimate the strength of this association. Between‑study heterogeneity was assessed with the Chi‑square‑based Q test. Overall, a possibly decreased risk of UC was associated with the SULT1A1 A/A polymorphism for the heterozygote model (OR=0.86, 95% CI: 0.76‑0.98, P=0.471). In the subgroup analysis by cancer type, the results indicated that individuals with the G/G genotype had a significantly higher bladder cancer (BC) risk (GA vs. GG: OR=0.88, 95% CI: 0.74‑0.99, P=0.626; GA/AA vs. GG: OR=0.85, 95% CI: 0.74‑0.97, P=0.504), which was contrary to the results of the upper urinary tract urothelial carcinoma (UTUC) group (AA vs. GG: OR=2.18, 95% CI: 1.28‑3.69; AA vs. GA/GG: OR=2.05, 95% CI: 1.24‑3.38). In addition, stratification by smoking status demonstrated that the Arg213His polymorphism was associated with a decreased risk of UC in non‑smokers (OR=0.70, 95% CI: 0.53‑0.92) but not in smokers (OR=0.85, 95% CI: 0.70‑1.03) under the dominant model. In conclusion, this meta‑analysis demonstrated a significant association between the SULT1A1 Arg213His polymorphism and BC. However, there was insufficient evidence to support a consistent association between this polymorphism and UC, partly due to the differences between BC and UTUC.

View Figures

View References

1	Chung CJ, Huang CY, Pu YS, Shiue HS, Su CT and Hsueh YM: The effect of cigarette smoke and arsenic exposure on urothelial carcinoma risk is modified by glutathione S-transferase M1 gene null genotype. Toxicol Appl Pharmacol. 266:254–259. 2013. View Article : Google Scholar : PubMed/NCBI
2	Milenkovic-Petronic D, Milojevic B, Djokic M, Sipetic-Grujicic S, Milojevic IG, Bumbasirevic U and Dzamic Z: The impact of tumor size on outcomes in patients with upper urinary tract urothelial carcinoma. Int Urol Nephrol. 46:563–569. 2014. View Article : Google Scholar : PubMed/NCBI
3	Tanaka N, Kikuchi E, Kanao K, et al: The predictive value of positive urine cytology for outcomes following radical nephroureterectomy in patients with primary upper tract urothelial carcinoma: a multi-institutional study. Urol Oncol. 32(48): e19–26. 2014. View Article : Google Scholar
4	Peng Q, Mo C, Tang W, et al: DNA repair gene XRCC3 polymorphisms and bladder cancer risk: a meta-analysis. Tumour Biol. 35:1933–1944. 2014. View Article : Google Scholar : PubMed/NCBI
5	Ross JS, Wang K, Al-Rohil RN, et al: Advanced urothelial carcinoma: next-generation sequencing reveals diverse genomic alterations and targets of therapy. Mod Pathol. 27:271–280. 2014. View Article : Google Scholar : PubMed/NCBI
6	Glatt H and Meinl W: Pharmacogenetics of soluble sulfotransferases (SULTs). Naunyn Schmiedebergs Arch Pharmacol. 369:55–68. 2004. View Article : Google Scholar : PubMed/NCBI
7	Ginsberg G, Guyton K, Johns D, et al: Genetic polymorphism in metabolism and host defense enzymes: implications for human health risk assessment. Crit Rev Toxicol. 40:575–619. 2010. View Article : Google Scholar : PubMed/NCBI
8	Wang YH, Juang GD, Hwang TI, et al: Genetic polymorphism of sulfotransferase 1A1, cigarette smoking, hazardous chemical exposure and urothelial cancer risk in a Taiwanese population. Int J Urol. 15:1029–1034. 2008. View Article : Google Scholar : PubMed/NCBI
9	Dooley TP, Obermoeller RD, Leiter EH, et al: Mapping of the phenol sulfotransferase gene (STP) to human chromosome 16p12.1-p11.2 and to mouse chromosome 7. Genomics. 18:440–443. 1993. View Article : Google Scholar : PubMed/NCBI
10	Pereira WO, Paiva AS, Queiroz JW, et al: Genetic polymorphism in the sulfotransferase SULT1A1 gene in cancer. Cancer Genet Cytogenet. 160:55–60. 2005. View Article : Google Scholar : PubMed/NCBI
11	Daniels J and Kadlubar S: Sulfotransferase genetic variation: from cancer risk to treatment response. Drug Metab Rev. 45:415–422. 2013. View Article : Google Scholar : PubMed/NCBI
12	Chou HC, Lang NP and Kadlubar FF: Metabolic activation of the N-hydroxy derivative of the carcinogen 4-aminobiphenyl by human tissue sulfotransferases. Carcinogenesis. 16:413–417. 1995. View Article : Google Scholar : PubMed/NCBI
13	Davey Smith G and Egger M: Meta-analyses of randomised controlled trials. Lancet. 350(1182)1997.
14	Mantel N and Haenszel W: Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst. 22:719–748. 1959.PubMed/NCBI
15	DerSimonian R and Laird N: Meta-analysis in clinical trials. Control Clin Trials. 7:177–188. 1986. View Article : Google Scholar : PubMed/NCBI
16	Ozawa S, Katoh T, Inatomi H, et al: Association of genotypes of carcinogen-activating enzymes, phenol sulfotransferase SULT1A1 (ST1A3) and arylamine N-acetyltransferase NAT2, with urothelial cancer in a Japanese population. Int J Cancer. 102:418–421. 2002. View Article : Google Scholar
17	Tsukino H, Kuroda Y, Nakao H, et al: Cytochrome P450 (CYP) 1A2, sulfotransferase (SULT) 1A1, and N-acetyltransferase (NAT) 2 polymorphisms and susceptibility to urothelial cancer. J Cancer Res Clin Oncol. 130:99–106. 2004. View Article : Google Scholar : PubMed/NCBI
18	Rouprêt M, Cancel-Tassin G, Comperat E, et al: Phenol sulfotransferase SULT1A1*2 allele and enhanced risk of upper urinary tract urothelial cell carcinoma. Cancer Epidemiol Biomarkers Prev. 16:2500–2503. 2007.
19	Covolo L, Placidi D, Gelatti U, et al: Bladder cancer, GSTs, NAT1, NAT2, SULT1A1, XRCC1, XRCC3, XPD genetic polymorphisms and coffee consumption: a case-control study. Eur J Epidemiol. 23:355–362. 2008. View Article : Google Scholar : PubMed/NCBI
20	Kellen E, Zeegers M, Paulussen A, et al: Does occupational exposure to PAHs, diesel and aromatic amines interact with smoking and metabolic genetic polymorphisms to increase the risk on bladder cancer?; The Belgian case control study on bladder cancer risk. Cancer Lett. 245:51–60. 2007. View Article : Google Scholar
21	Hung RJ, Boffetta P, Brennan P, et al: GST, NAT, SULT1A1, CYP1B1 genetic polymorphisms, interactions with environmental exposures and bladder cancer risk in a high-risk population. Int J Cancer. 110:598–604. 2004. View Article : Google Scholar : PubMed/NCBI
22	Cui X, Lu X, Hiura M, et al: Association of genotypes of carcinogen-metabolizing enzymes and smoking status with bladder cancer in a Japanese population. Environ Health Prev Med. 18:136–142. 2013. View Article : Google Scholar : PubMed/NCBI
23	Zheng L, Wang Y, Schabath MB, Grossman HB and Wu X: Sulfotransferase 1A1 (SULT1A1) polymorphism and bladder cancer risk: a case-control study. Cancer Lett. 202:61–69. 2003. View Article : Google Scholar : PubMed/NCBI
24	Yu X, Kubota T, Dhakal I, et al: Copy number variation in sulfotransferase isoform 1A1 (SULT1A1) is significantly associated with enzymatic activity in Japanese subjects. Pharmgenomics Pers Med. 6:19–24. 2013.PubMed/NCBI
25	Tengström M, Mannermaa A, Kosma VM, Hirvonen A and Kataja V: SULT1A1 rs9282861 polymorphism - a potential modifier of efficacy of the systemic adjuvant therapy in breast cancer? BMC Cancer. 12:2572012.PubMed/NCBI
26	Coughtrie MW, Gilissen RA, Shek B, et al: Phenol sulphotransferase SULT1A1 polymorphism: molecular diagnosis and allele frequencies in Caucasian and African populations. Biochem J. 337:45–49. 1999. View Article : Google Scholar : PubMed/NCBI
27	Munafò MR and Flint J: Meta-analysis of genetic association studies. Trends Genet. 20:439–444. 2004.PubMed/NCBI
28	Patel N, Arya M, Muneer A, et al: Molecular aspects of upper tract urothelial carcinoma. Urol Oncol. 32(28): e11–20. 2014. View Article : Google Scholar
29	Catto JW, Azzouzi AR, Amira N, et al: Distinct patterns of microsatellite instability are seen in tumours of the urinary tract. Oncogene. 22:8699–8706. 2003. View Article : Google Scholar : PubMed/NCBI
30	Catto JW, Azzouzi AR, Rehman I, et al: Promoter hypermethylation is associated with tumor location, stage, and subsequent progression in transitional cell carcinoma. J Clin Oncol. 23:2903–2910. 2005. View Article : Google Scholar : PubMed/NCBI
31	Roupret M, Catto J, Coulet F, et al: Microsatellite instability as indicator of MSH2 gene mutation in patients with upper urinary tract transitional cell carcinoma. J Med Genet. 41:e912004. View Article : Google Scholar : PubMed/NCBI
32	Bermejo JL, Eng C and Hemminki K: Cancer characteristics in Swedish families fulfilling criteria for hereditary nonpolyposis colorectal cancer. Gastroenterology. 129:1889–1899. 2005. View Article : Google Scholar : PubMed/NCBI
33	Green DA, Rink M, Xylinas E, et al: Urothelial carcinoma of the bladder and the upper tract: disparate twins. J Urol. 189:1214–1221. 2013. View Article : Google Scholar : PubMed/NCBI
34	Liang FX, Bosland MC, Huang H, et al: Cellular basis of urothelial squamous metaplasia: roles of lineage heterogeneity and cell replacement. J Cell Biol. 171:835–844. 2005. View Article : Google Scholar : PubMed/NCBI
35	Klug SJ, Ressing M, Koenig J, et al: TP53 codon 72 polymorphism and cervical cancer: a pooled analysis of individual data from 49 studies. Lancet Oncol. 10:772–784. 2009. View Article : Google Scholar : PubMed/NCBI
36	Tyler A: Urothelial cancers: ureter, renal pelvis, and bladder. Semin Oncol Nurs. 28:154–162. 2012. View Article : Google Scholar : PubMed/NCBI
37	Crivelli JJ, Xylinas E, Kluth LA, et al: Effect of smoking on outcomes of urothelial carcinoma: a systematic review of the literature. Eur Urol. 65:742–754. 2014. View Article : Google Scholar : PubMed/NCBI